Genpharmasec Intrinsic Value
Genpharmasec (GENPHARMA) median intrinsic value is ₹2.10 from 8 valuation models (range ₹1–₹3), vs current price ₹1.05 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. For current market price and key ratios, visit Genpharmasec share price chart.
GENPHARMA Valuation Methods Summary — DCF, Graham Number & P/E
Genpharmasec intrinsic value across 8 models vs current price ₹1.05 — upside/downside and value range per method. Read GENPHARMA dividend track record for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹0.96 | ₹0.77 - ₹1.15 | -8.6% | EPS: ₹0.08, Sector P/E: 12x |
| Book Value Method | asset | ₹2.62 | ₹2.36 - ₹2.88 | +149.5% | Book Value/Share: ₹12.00, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹2.10 | ₹1.89 - ₹2.31 | +100.0% | Revenue/Share: ₹41.45, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹2.10 | ₹1.89 - ₹2.31 | +100.0% | EBITDA: ₹12.00Cr, EV/EBITDA: 6x |
| PEG Ratio Method | growth | ₹0.51 | ₹0.46 - ₹0.56 | -51.4% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹0.66 | ₹0.59 - ₹0.73 | -37.1% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹2.10 | ₹1.89 - ₹2.31 | +100.0% | ROE: 6.1%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹3.15 | ₹2.83 - ₹3.47 | +200.0% | EPS: ₹0.08, BVPS: ₹12.00 |
GENPHARMA Intrinsic Value vs Market Price — All Valuation Models
Genpharmasec fair value range ₹1–₹3 vs current market price ₹1.05 across 8 valuation models. Analyse Genpharmasec shareholding analysis to track promoter, FII and institutional holdings.
GENPHARMA Intrinsic Value Analysis — Undervalued or Overvalued?
Genpharmasec median intrinsic value ₹2.10, current price ₹1.05 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of GENPHARMA?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Genpharmasec (GENPHARMA) is ₹2.10 (median value). With the current market price of ₹1.05, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹0.51 to ₹3.15, indicating ₹0.51 - ₹3.15.
Is GENPHARMA undervalued or overvalued?
Based on our multi-method analysis, Genpharmasec (GENPHARMA) appears to be trading below calculated value by approximately 100.0%.
GENPHARMA Financial Health — Key Ratios vs Industry Benchmarks
Genpharmasec financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 3.12 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 6.1% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 4.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.65x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
GENPHARMA Cash Flow Quality — Operating & Free Cash Flow
Genpharmasec operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹3 Cr | ₹-5 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹-3 Cr | ₹-17 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-3 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |